



## Microbial infections in eight genomic subtypes of Chronic Fatigue Syndrome / Myalgic Encephalomyelitis (CFS/ME)

Lihan Zhang, John Goudh, David Christmas, Derek Matthey, Selwyn Richards, Janice Main, Derek Enlander, David Honeybourne, Jon Ayres, David J Nutt and Jonathan Kerr

*J. Clin. Pathol.* published online 2 Dec 2009;  
doi:10.1136/jcp.2009.072561

---

Updated information and services can be found at:  
<http://jcp.bmj.com/cgi/content/abstract/jcp.2009.072561v1>

---

*These include:*

- |                               |  |
|-------------------------------|--|
| <b>Open Access</b>            | This article is free to access   |
| <b>Rapid responses</b>        | You can respond to this article at:<br><a href="http://jcp.bmj.com/cgi/eletter-submit/jcp.2009.072561v1">http://jcp.bmj.com/cgi/eletter-submit/jcp.2009.072561v1</a> |
| <b>Email alerting service</b> | Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article  |
- 

### Notes

---

**Online First** contains unedited articles in manuscript form that have been peer reviewed and accepted for publication but have not yet appeared in the paper journal (edited, typeset versions may be posted when available prior to final publication). Online First articles are citable and establish publication priority; they are indexed by PubMed from initial publication. Citations to Online First articles must include the digital object identifier (DOIs) and date of initial publication.

---

To order reprints of this article go to:  
<http://journals.bmj.com/cgi/reprintform>

To subscribe to *Journal of Clinical Pathology* go to:  
<http://journals.bmj.com/subscriptions/>

Running head: Microbial infections in CFS/ME subtypes

**Microbial infections in eight genomic subtypes of Chronic Fatigue Syndrome /  
Myalgic Encephalomyelitis (CFS/ME)**

Lihan Zhang,<sup>1</sup> John Gough,<sup>1</sup> David Christmas,<sup>2</sup>  
Derek L Matthey,<sup>3</sup> Selwyn CM Richards,<sup>4</sup> Janice Main,<sup>5</sup> Derek Enlander,<sup>6</sup>  
David Honeybourne,<sup>7</sup> Jon G Ayres,<sup>8</sup> David J Nutt,<sup>2</sup> Jonathan R Kerr.<sup>1</sup>

<sup>1</sup>Department of Cellular & Molecular Medicine, St George's University of London, London, UK; <sup>2</sup>Psychopharmacology Unit, Dept of Community Based Medicine, University of Bristol, Bristol, UK; <sup>3</sup>Staffordshire Rheumatology Centre, Stoke on Trent, UK; <sup>4</sup>Dorset CFS Service, Poole Hospital, Dorset, UK; <sup>5</sup>Dept of Infectious Diseases and General Medicine, Imperial College London, St Mary's Hospital, London, UK; <sup>6</sup>New York ME / CFS Service, 860 Fifth Avenue, New York, USA; <sup>7</sup>Dept of Respiratory Medicine, Birmingham Heartlands Hospital, UK; <sup>8</sup>Dept of Environmental and Occupational Medicine, University of Birmingham, UK.

Reprints or correspondence: Dr Jonathan R Kerr, Room 2.267, Jenner Wing, St George's University of London, Cranmer Terrace, London SW17 0RE, UK. Email: [jkerr@sgul.ac.uk](mailto:jkerr@sgul.ac.uk).

Word count (abstract): 199

Word count (text): 3,479

## Abstract

We have previously reported genomic subtypes of CFS/ME based on expression of 88 human genes. In this study we attempted to reproduce these findings, determine specificity of this signature to CFS/ME, and test for associations between CFS/ME subtype and infection.

We determined expression levels of 88 human genes in blood of 61 new patients with idiopathic CFS/ME (according to Fukuda criteria), 6 patients with Q-fever associated CFS/ME from the Birmingham Q-fever outbreak (according to Fukuda criteria), 14 patients with endogenous depression (according to DSM-IV criteria) and 18 normal blood donors. In patients with CFS/ME differential expression was confirmed for all 88 genes. Q-CFS/ME patients had similar patterns of gene expression to idiopathic CFS/ME. Gene expression in endogenous depression patients was similar to that in the normal controls, except for upregulation of five genes (APP, CREBBP, GNAS, PDCD2, PDCD6).

Clustering of combined gene data in CFS/ME patients for this and our previous study (n=117 CFS/ME patients) revealed genomic subtypes with distinct differences in SF-36 scores, clinical phenotypes, severity and geographical distribution. Antibody testing for Epstein-Barr virus (EBV), enterovirus, *Coxiella burnetii* and parvovirus B19 revealed evidence of subtype-specific relationships for EBV and enterovirus, the two most common infectious triggers of CFS/ME.

**Keywords:** Chronic fatigue syndrome, myalgic encephalomyelitis, subtypes, gene expression, endogenous depression, Epstein-Barr virus, parvovirus B19, *Coxiella burnetii*, enterovirus.

## Introduction

Chronic Fatigue Syndrome / Myalgic Encephalomyelitis (CFS/ME) is a disease characterised by severe and debilitating fatigue, sleep abnormalities, impaired memory and concentration, and musculoskeletal pain [1]. In the Western world, the population prevalence is estimated to be of the order of 0.5% [2,3]. Research studies have identified various features relevant to the pathogenesis of CFS/ME such as viral infection, immune abnormalities and immune activation, exposure to toxins, chemicals and pesticides, stress, hypotension, lymphocyte abnormalities and neuroendocrine dysfunction. However, the precise underlying disease mechanisms and means by which these abnormalities inter-relate in CFS/ME patients, remain to be clarified [4,5].

Various groups have analysed the gene expression in peripheral blood of patients with CFS/ME and in all of these studies, genes of immunity and defense are prominent. Following a pilot microarray study which identified 16 abnormally expressed genes in CFS/ME [6], we have reported on a comprehensive microarray study which reveals abnormal expression of 88 human genes in patients with CFS/ME [7]. Clustering of these data revealed 7 genomic subtypes of CFS/ME with distinct differences in SF-36 scores, clinical phenotypes, severity and geographical distribution [7,8]. However, remaining questions relate to reproducibility and the specificity of these gene abnormalities to CFS/ME and possible associations with infectious agents.

In this study, we set out to determine whether these findings were reproducible in fresh subjects, whether the previously reported dysregulation of these genes also occurred in drug-free patients with endogenous depression, and whether there was any relationship between particular microbial infections and CFS/ME genomic subtype. Results show that these findings are reproducible, and that gene expression in endogenous depression patients was markedly different to that in CFS/ME patients, and was similar to that in the normal controls, in terms of these 88 human genes. Also, clustering of gene data revealed 8 genomic subtypes with distinct clinical differences, and several of these had interesting associations with particular microbial infections.

## Methods

### Subject enrolment, clinical characterisation and blood sampling

CFS/ME patients (n=62), who lived in Birmingham (n=6), Bristol (n=3), London (n=9) and New York (n=44) were diagnosed according to Fukuda diagnostic criteria for CFS/ME [1] and enrolled into the study. All these suffered from idiopathic CFS/ME except the 6 Birmingham patients, who suffered from CFS/ME which had been triggered by laboratory documented Q fever. Patients with psychiatric disease were excluded using the Minnesota International Neuropsychiatric Interview (MINI), thus ensuring that none of our CFS/ME patients was suffering from major psychiatric disease or abuse of alcohol or other drugs. Clinical and Q-PCR data for these new patients were combined with 55 CFS/ME patients from a previous study [7,8], giving a total of 116 CFS/ME patients, who lived in Birmingham (n=6), Bristol (n=14), Leicester (n=1), London (n=12), New York (n=55) and Dorset (n=28).

Patients suffering from endogenous depression (n=14) were enrolled from Bristol, UK, and surrounding area. These patients fulfilled DSM-IV criteria, had not smoked within the previous year, and had not taken antidepressants in the previous year.

Healthy normal blood donors enrolled from the Dorset National Blood Service (NBS) (n=29) were used as a comparison group. Restrictions imposed by the NBS on those allowed to donate blood are outlined elsewhere [6].

For all patient groups, individuals who smoked in the previous year, who abused alcohol or other drugs, were currently taking (or were within 3 months of taking) antibiotics, steroids, cytotoxic drugs or antidepressants were excluded from the study.

For all enrolled subjects (patients and controls), according to the recommendations of the International CFS Study Group [9], severity of physical and mental fatigue was assessed using the Chalder Fatigue Scale [10]; level of disability was assessed using the Medical Outcomes Survey Short Form-36 (SF-36); accompanying symptoms were characterised using the Somatic and Psychological Health Report (SPHERE); sleep abnormalities were assessed using the Pittsburgh Sleep Questionnaire; and assessment of type and severity of pain was performed using the McGill Pain Questionnaire.

Patients and controls gave informed written consent according to guidance of the Wandsworth Research Ethics Committee (approval number 05/Q0803/137). For the New York patients, approval of the local Institutional Review Board was obtained. The human experimentation guidelines of the US Department of Health and Human Services were followed in this study.

2.5ml blood was taken from both CFS/ME patients and normal blood donors (as part of routine blood donation) into PAXgene tubes (PreAnalytix) and total RNA extracted using the PAXgene blood RNA kit (PreAnalytix), according to the instructions of the manufacturer. RNA quality and amount were confirmed by micro-spectrophotometry (Nanodrop, Rockland, DE, USA). Total RNA samples used in this study had an absorbance ratio (A260/280) of 1.9-2.0.

### QPCR

QPCR (Applied Biosystems, Foster City, CA, USA) was used to quantitate the amount of mRNA for 88 CFS/ME-associated human genes by the comparative method, using custom 384-well low-density arrays (LDA) and the ABI PRISM 7900HT instrument (Applied Biosystems) with glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as the endogenous control gene. Experiments were performed in triplicate using the protocol described previously [6,7]. Data was displayed using SDS 2.2 software (ABI), discordant data between replicates omitted, and results for each LDA calculated, and loaded into ABI SDS v2.2 Enterprise Edition software.

The threshold cycle (Ct) for each test gene in each sample was compared to that for GAPDH to calculate a  $\Delta\text{Ct}$  value.  $\Delta\text{Ct}$  values for were then normalised to the calibrator sample to give the  $\Delta\Delta\text{Ct}$  values. Relative quantities (RQ) ( $2^{-\Delta\Delta\text{Ct}}$ ) of each mRNA of interest were then calculated. Samples showing a difference between minimum and maximum RQ values of  $\geq 100$  (indicating poor replicate concordance) were excluded. The t-test was used to compare mean RQ values between groups. A p value of  $\leq 0.05$  was taken to be significant.

### Clustering of QPCR-generated gene values of CFS/ME patients

Ct values for all 88 CFS/ME-associated genes in 117 CFS/ME patients were then normalised and clustered using Genesis software [11]. For each of the eight CFS/ME subtypes identified using this approach, mean RQ values were calculated for each gene, and used to generate fold-difference (CFS/ME / Normal) values for each gene

in each CFS/ME subtype. Mean fold-difference values for each gene in each CFS/ME subtype were then clustered with and without normalisation / median centering using Cluster version 2.11 software and visualised using Treeview version 1.60 software [12]. The clustering algorithm in both of these software programs has been described previously [12].

#### Detection of anti-microbial antibodies

IgM and IgG antibodies specific to 4 microbes which are well recognised to trigger CFS/ME were detected by ELISA, according to the manufacturer's instructions; Epstein-Barr virus (viral capsid antigen (VCA) IgM and IgG, early antigen (EA) IgG, and Epstein-Barr nuclear antigen (EBNA) IgG) (Meridien Bioscience Inc, Cincinnati, OH, USA), enterovirus (all serotypes) (Virion Serion, Wurzburg, Germany), parvovirus B19 (viral protein 2 (VP2) IgM and IgG) (Biotrin, Dublin, Ireland) and *Coxiella burnetii* (phase I and II IgG) (Virion Serion, Wurzburg, Germany).

#### Statistical testing

Testing of the significance of associations of gene expression levels with different patient groups was performed using a 2-tailed t-test. Testing of the significance of association between clinical parameters and CFS/ME genomic subtype was performed using  $\chi^2$ , ANOVA and the Mann-Whitney U tests. Testing of the significance of association between microbial markers in CFS/ME and CFS/ME subtypes was performed using  $\chi^2$  analyses, and ANOVA.

## Results

### Subjects and clinical characterisation

A total of 117 CFS/ME patients fulfilling CDC diagnostic criteria were used in this study. For 55 CFS/ME patients, previously published data was used, while the remaining 62 CFS/ME patients had not previously been tested; for 6 of these, CFS/ME disease had been triggered by laboratory documented *C. burnetii* infection. In addition, 14 patients with endogenous depression and 18 normal blood donors were also studied.

A summary of the clinical details of these subjects is shown in Table 1. In general, all CFS/ME groups had similar profiles of symptoms and mean clinical scores, and Q-CFS/ME was phenotypically similar to the other CFS/ME patients for whom the triggering factors were unknown. Endogenous depression patients had a markedly low prevalence of numbness / tingling and tender lymphadenopathy, and lower bodily pain as indicated by the McGill pain questionnaire mean score, as compared with CFS/ME. Normal blood donors had very low prevalence of all symptoms, little fatigue (Chalder), pain (McGill), associated symptoms (SPHERE), normal sleep (PSQI) and high SF36 total scores (Table 1), as would be expected.

### QPCR

Quantitative PCR was carried out using TaqMan primers/probes specific for 88 human genes which were previously found to be differentially expressed in CFS/ME patients [7]. This analysis confirmed that most of these genes differed significantly between CFS/ME and Normal groups. Of the 88 genes, 84 were found to be upregulated and 4 were downregulated (HIF1A, IL7R, PAPOLA, SHPRH), which is similar to what we reported previously [7]. Gene expression in patients with Q-CFS/ME was also found to be markedly different to the normal group, and very similar to that found in patients with CFS/ME. Gene expression in patients with endogenous depression did not differ markedly from that in the normal group, except in the case of five genes (APP, CREBBP, GNAS, PDCD2, PDCD6), where significant upregulation (fold-difference  $\geq 1.5$ ) was found (Table 2).

### Genomic CFS/ME subtypes

Clustering of  $\Delta$ Ct values for the 88 CFS/ME-associated genes in the 117 CFS/ME patients identified 8 subtypes (designated A – H); consisting of 27, 6, 19, 5, 21, 13, 19 and 4 CFS/ME patients, respectively. There were 3 patients whose gene profile

did not fit into any of these 8 subtype groupings. Mean fold difference values for each CFS/ME subtype are shown in Table 3 and Figure 1. Most genes in each subtype were shown to be upregulated (Table 3 & Figure 1).

The relationship between the subtypes of the present study and those of the previous study which examined only 55 CFS/ME patients [7,8] maybe difficult to determine. As these subtypes are derived using clustering, which finds similar groups on the basis of gene expression values, there is no means to predict the outcome of the clustering. As there was only moderate preservation of the previous CFS/ME patient groupings in the present study, we have designated the subtypes, A – H, to distinguish them from those of the previous study, which were designated 1 – 7 [7].

Analysis of sex ratios for each subtype reveals that subtype D is made up of females only, subtype H is made up of equal number of males and females, and the remaining subtypes are made up predominantly of females.

It is particularly interesting that 5 of 6 CFS/ME patients with Q-CFS/ME clustered in the same subtype (subtype A).

The clinical phenotype was distinct between subtypes; subtype D was the most severe, having the lowest scores for SF36 modules RP, VIT, GH, BP and Total score, and the highest frequency of occurrence of muscle pain and sleep problems. Subtype B was the least severe, having the highest scores for SF36 modules RP, GH, MH and total score. Subtype B had a higher median score for the SF36-RP (physical role) than all the others combined (87.5 v 0),  $p=0.04$ ; Mann-Whitney test). However, subtype B had the highest frequency of cognitive dysfunction, muscle weakness and post-exertional malaise. Subtype B showed a higher frequency of cognitive dysfunction than all non-subtype B patients combined ( $p=0.03$ ) and showed an increased severity and duration of headache compared with all non-subtype B patients combined ( $p=0.02$ ). Subtype B also had a higher median score for mental fatigue (Chalder scale) than all non-subtype B patients combined although this did not reach significance (9.5 v 7.0;  $p=0.06$ ). Subtypes B and C had the best mental health scores, and subtypes A and F had the worst (Figure 2, panels A & B).

Subtype E had a higher median score for SF36-VIT (vitality) than all the others combined (35.0 v 15.0;  $p=0.05$ ; Mann-Whitney test). Subtype E had the highest frequency of GI problems. Patients of subtype F showed a higher frequency of

increased severity of numbness / tingling compared with all non-subtype F patients combined ( $p=0.03$ ). Patients of subtype H showed an increased frequency of severity of sore throat compared with all non-subtype H patients combined ( $p=0.01$ ) (Figure 2, panels A & B).

As regards possible association of subtype with geographical location, there was evidence to support this, as we found previously [7]. Predominant subtypes in each geographical location were as follows; Birmingham (subtype A), Bristol (subtype C), Leicester (subtype C), London (subtype C, then subtype G), New York (subtype E, then subtypes G, A, C and F), Dorset (subtypes A, F, B). Subtype A was prominent in New York, Birmingham and Dorset; subtype B was prominent in Dorset; subtype C was prominent in Bristol, London and New York; subtype D was prominent in Bristol and London; subtype E was prominent in New York; subtype F was prominent in Dorset and New York; subtype G was prominent in New York; subtype H was prominent in Dorset (Figure 2, panel C).

#### Microbial infections

The presence and titre of specific antibodies (IgM and IgG) to four treatable microbial infections which are well recognised as triggers of CFS/ME were also determined in serum samples; these were Epstein-Barr virus, enterovirus, parvovirus B19 and *Coxiella burnetii*. The seroprevalence (proportion of subjects who were positive for specific IgG) of each of these infections was typical of the general population; EBV (based on VCA IgG) (88%), enterovirus (49%), parvovirus B19 (based on VP2 IgG) (74%), *C. burnetii* (based on phase I or II IgG) (10%). Of those 11 patients who had *C. burnetii* IgG, 5 were patients whose CFS/ME disease had been triggered by laboratory documented Q fever.

CFS/ME patients with acute infection with one or more of these agents (IgM or acute phase IgG) were also detected; EBV (based on VCA IgM) ( $n=3$ ), enterovirus ( $n=6$ ), parvovirus B19 ( $n=1$ ), *C. burnetii* (based on phase II IgG) ( $n=12$ ). Of those 12 patients who were positive for *C. burnetii* phase II IgG, 5 were patients with Q-CFS/ME. There were no acute infections detected in the normal group.

Regarding EBV serology, there were also associations between CFS/ME subtype and both EBV VCA IgM titre ( $p=0.0038$ ) and EBV EBNA IgG titre ( $p=0.0011$ ) (Figure 2, panel D). Using the EBV markers VCA IgM, VCA IgG, EA IgG and EBNA IgG, we determined the EBV serostatus of infection for each subject (ie. seronegative,

primary infection / reactivation, late phase of infection). Among the CFS/ME patients, there were 11 seronegative, 61 primary / reactivation, and 39 late phase of infection, as compared the Normal group, in which there was 1 seronegative, 8 primary / reactivation, and 19 late phase of infection ( $\chi^2 = 9.91$ , degrees of freedom = 2,  $p = 0.007$ ) (Figure 2, panel E).

The distribution of CFS/ME patients with EBV serostatus categories, seronegative, primary / reactivation and late phase of infection, across the 8 CFS/ME genomic subtypes is shown in Figure 2, panel E. In the normal persons, the predominant category of EBV serostatus was late phase of infection, while in the CFS/ME subtypes, the predominant category of EBV serostatus was primary / reactivation, which was seen in subtypes A, B, C, D, F and H. Subtype G had equal numbers of primary / reactivation and late phase, while subtype E had a predominance of late phase subjects, but also had 5 seronegative subjects. This distribution was found to be almost statistically significant ( $\chi^2 = 25.9$ , degrees of freedom = 16,  $p = 0.055$ ).

#### EBV-associated genes in each CFS/ME subtype

Within the CFS/ME-associated gene signature of 88 human genes, there were 12 which have recognised associations with EBV infection; these associations have been summarised previously [7]. The fold-difference values, for each of these 12 genes in each CFS/ME subtype / normal, were analysed using ANOVA, for significant associations. With all 12 genes, there was a trend which did not reach significance ( $df = 89, p=0.119$ ). However, when GABPA and EGR1 were removed from the analysis, the remaining 10 genes showed a striking association with subtype (ANOVA,  $df=73, p=0.0001$ ) (Figure 2, panel F).

## Discussion

We have previously reported the differential expression of 88 human genes in CFS/ME and evidence of clinically relevant subtypes [7,8]. In the present study, we have confirmed this differential expression in 62 additional and previously untested CFS/ME patients. Combining the previous cohort and the new cohort, we have found evidence of 8 genomic CFS/ME subtypes with marked differences in global functioning, clinical symptoms, levels of severity and geographical distribution. The function of these genes and their networks has been published previously [7].

We have addressed the question of the specificity of these 88 genes to CFS/ME, by testing drug-free patients with endogenous depression. The fact that only 5 of these genes were abnormally expressed in endogenous depression patients as compared with normals, supports the view that CFS/ME and endogenous depression are biologically distinct, and that the psychological features of CFS/ME are in fact secondary to the pathogenesis.

It is particularly interesting that 5 of 6 CFS/ME patients with Q-CFS/ME clustered in the same subtype (subtype A). As these patients had suffered from CFS/ME for several years, this finding suggests that they have a common underlying theme, which maybe stable for a long time after the onset of disease. In view of this, and as various genes within this human gene signature are closely linked with EBV infection (NFKB1, EGR1, ETS1, GABPA, CREBBP, CXCR4, EBI2, HIF1A, JAK1, IL6R, IL7R, PIK3R1), and enterovirus infection (EIF4G1), we tested the serum samples for markers for four treatable microbial infections which are well recognised to trigger CFS/ME; EBV, enterovirus, parvovirus B19 and *C. burnetii* (the agent of Q fever), with the hypothesis that these genomic CFS/ME subtypes may represent host responses to particular infectious agents.

One patient with subtype E was suffering from acute parvovirus B19 at the time of sampling. This patient's symptoms were typical of CFS/ME, but this is not unexpected as B19 is a recognized trigger for CFS/ME [13]. The importance of testing for these infections is illustrated here as we have shown previously that B19-CFS/ME is highly responsive to treatment with intravenous immunoglobulin (IVIG) [14].

Six patients were suffering from acute enterovirus infections (of undetermined serotype) at the time of sampling, but there was no subtype relationship as 2 patients

occurred in each of subtypes A, E and G, respectively. Enteroviruses have long been recognized to trigger CFS/ME [15], and they have been detected in the stool [16] and stomach epithelium [17] in CFS/ME patients. Detection in the stomach has been shown to be associated with gastrointestinal symptoms in CFS/ME patients [17]. However, in the present study, subtypes A, E and G did not exhibit GI symptoms more prominently than the other subtypes.

Twelve CFS/ME patients and 1 Normal subject exhibited IgG to *Coxiella burnetii* phase II antigen, suggesting possible acute infection. Five of these CFS/ME patients were those with Q-CFS/ME. The patients in whom these antibodies were detected were of subtypes A, B, D, E, and G. Therefore, apart from the patients with Q-CFS/ME (whose CFS/ME disease onset was associated with laboratory documented acute Q fever), there were no subtype specific relationships with *C. burnetii* antibodies.

The subtype associations with EBV and EBV-linked genes are interesting, suggesting differences in the role of EBV and consequent host responses in the different subtypes. The finding of a noticeably large proportion of CFS/ME patients who were EBV seronegative (10%), compared to 4% in the normal group was quite surprising, given the strong link between EBV and CFS/ME. The fact that 5 of these 11 seronegative cases occurred in subtype E is interesting, but remains unexplained at present.

It has been recognized for some time that subtypes of CFS/ME exist, and it has been thought that these subtypes may, at least in part, reflect particular aetiological factors [18]. A symptom-based approach has had some success in identifying musculoskeletal, inflammatory and neurological subtypes [19], however, these groups had only minor differences in overall functional severity in contrast to those of the present study.

It is intriguing that it is possible to identify CFS/ME subtypes on the basis of expression values for these 88 genes, and even more so that these subtypes have distinct clinical phenotypes, with marked differences in the occurrence of particular symptoms and their severity. However, what precise sequence of events are involved in the genesis of the gene signatures in each subtype remains to be elucidated. Further work is urgently required to validate and develop these findings.

### Acknowledgements

This work was supported by grants from the Chronic Fatigue Syndrome Research Foundation (CFSRF), UK (salaries of JG and DC), Sir Joseph Hotung (salaries of JRK and BB), and a Wellcome Trust Vacation Scholarship (awarded to LZ). We thank Dr Frank Boulton, Ms Julie Williams, Mr Peter Rogers, Ms Diana Carr and the NBS teams of East Dorset for their help in enrolment and sampling of normal blood donors; Beverley Burke, Deepika Devanur, Joanne Hunt and Robert Petty for help with sample processing and omission of non-concordant Q-PCR data, and all the patients with CFS/ME and blood donors for their participation.

This work was presented at the International Association for Chronic Fatigue Syndrome / Myalgic Encephalomyelitis (IACFSME), Reno, Nevada, USA, March 2009.

Competing interests – none to declare

### **Take Home Messages**

Expression of 88 human genes was confirmed as being significantly different between CFS/ME patients and normal controls.

Gene expression in endogenous depression patients was similar to that in the normal controls.

CFS/ME patients can be grouped into Genomic subtypes which have different clinical phenotypes.

There was evidence of subtype-specific relationships for Epstein-Barr virus (EBV) and enterovirus, the two most common triggers for CFS/ME.

The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, an exclusive licence (or non-exclusive for government employees) on a worldwide basis to the BMJ Publishing Group Ltd and its Licensees to permit this article to be published in Journal of Clinical Pathology editions and any other BMJPG products to exploit all subsidiary rights, as set out in our licence <http://jcp.bmjournals.com/ifora/licence.pdf>

## References

1. Fukuda K, Straus SE, Hickie I, Sharpe MC, Dobbins JG, Komaroff A. The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. *Ann Intern Med* **1994**;121:953-9.
2. A Report of the CFS/ME Working Group. Department of Health, January **2002**. (<http://www.doh.gov.uk/cmofcsmereport/>).
3. Papanicolaou DA, Amsterdam JD, Levine S, McCann SM, Moore RC, Newbrand CH, Allen G, Nisenbaum R, Pfaff DW, Tsokos GC, Vgontzas AN, Kales A. Neuroendocrine aspects of chronic fatigue syndrome. *Neuroimmunomodulation* **2004**;11(2):65-74.
4. Komaroff, A.L., Buchwald, D. Chronic fatigue syndrome: an update. *Annu Rev Med* **1998**;49:1-13.
5. Devanur LD, Kerr JR. Chronic Fatigue Syndrome. *J Clin Virol* **2006**;37(3):139-50.
6. Kaushik N, Fear D, Richards SC, McDermott CR, Nuwaysir EF, Kellam P, Harrison TJ, Wilkinson RJ, Tyrrell DA, Holgate ST, Kerr JR. Gene expression in peripheral blood mononuclear cells from patients with chronic fatigue syndrome. *J Clin Pathol* **2005**;58(8):826-32.
7. Kerr JR, Petty R, Burke B, et al. Differentially expressed genes in Chronic Fatigue Syndrome / Myalgic Encephalomyelitis (CFS/ME) patients reveal seven subtypes with distinct clinical phenotypes. *Journal of Infectious Diseases* **2008**;197:1171-84.
8. Kerr JR, Burke B, Petty R, Gough J, Fear D, Matthey DL, Axford JS, Dalgleish AG, Nutt DJ. Seven genomic subtypes of chronic fatigue syndrome / myalgic encephalomyelitis: a detailed analysis of gene networks and clinical phenotypes. *J Clin Pathol*. **2008**;61(6):730-9.
9. Reeves, W.C., Lloyd, A., Vernon, S.D., Klimas, N., Jason, L.A., Bleijenberg, G., Evengard, B., White, P.D., Nisenbaum, R., Unger, E.R. Identification of ambiguities in the 1994 chronic fatigue syndrome research case definition and recommendations for resolution. *BMC Health Serv Res* **2003**;3:25.

10. Chalder, T., Berelowitz, G., Pawlikowska, T., Watts, L., Wessely, S., Wright, D., Wallace, E.P. Development of a fatigue scale. *J Psychosom Res* **1993**;37:147-153.
11. Sturn A, Quackenbush J, Trajanoski Z. Genesis: cluster analysis of microarray data. *Bioinformatics*. **2002**;18(1):207-8.
12. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. *Proc Natl Acad Sci U S A*. **1998**;8;95(25):14863-8.
13. Kerr JR, Bracewell J, Laing I, et al. Chronic fatigue syndrome (CFS) and arthralgia following parvovirus B19 infection. *J Rheumatol* **2002**;29:595–602.
14. Kerr JR, Cunniffe VS, Kelleher P, Bernstein RM, Bruce IN. Successful intravenous immunoglobulin therapy in 3 cases of parvovirus B19-associated chronic fatigue syndrome. *Clin Infect Dis*. **2003**;36(9):e100-6.
15. Kerr JR. Enterovirus infection of the stomach in chronic fatigue syndrome/myalgic encephalomyelitis. *J Clin Pathol*. **2008**;61(1):1-2.
16. Yousef GE, Bell EJ, Mann GF, Murugesan V, Smith DG, McCartney RA, Mowbray JF. Chronic enterovirus infection in patients with postviral fatigue syndrome. *Lancet*. **1988**;1(8578):146-50.
17. Chia JK, Chia AY. Chronic fatigue syndrome is associated with chronic enterovirus infection of the stomach. *J Clin Pathol* **2008**;61:43–8.
18. Jason LA, Corradi K, Torres-Harding S, Taylor RR, King C. Chronic fatigue syndrome: the need for subtypes. *Neuropsychol Rev*. **2005**;15(1):29-58.
19. Janal MN, Ciccone DS, Natelson BH. Sub-typing CFS patients on the basis of 'minor' symptoms. *Biol Psychol*. **2006**;73(2):124-31.

## FIGURE LEGENDS

### **Figure 1.**

Absolute fold-difference values (mean RQ in CFS/ME patients / mean RQ in normal controls) for each of 88 CFS/ME-associated genes in 8 CFS/ME subtypes (A – H).

### **Figure 2, panel A.**

SF36 domain and total scores for each CFS/ME subtype, all CFS/ME subjects and Normals; physical function, physical role (RP), bodily pain (BP), general health (GH), vitality (VIT), social functioning (SF), emotional role (RE), mental health (MH) and total score (Total).

### **Figure 2, panel B.**

Scores indicating occurrence and severity of 11 clinical symptoms and results of neurocognitive testing for each CFS/ME subtype, all CFS/ME subjects and Normals; headache (HA), sore throat (ST), swollen glands (GLA), cognitive defect (COG), muscle pain (MP), joint pain (JP), muscle weakness (MW), postexertional malaise (PEM), sleep problems (SLE), fainting / dizziness (F/D), gastrointestinal complaints (GI), numbness / tingling (N/T); Spatial span (SSP), Verbal recognition memory (VRM).

### **Figure 2, panel C.**

Histogram showing the numbers of CFS/ME patients of each subtype occurring in each of the 6 geographical locations.

### **Figure 2, panel D.**

Epstein Barr virus (EBV) antibody titres (VCA IgM, VCA IgG, EA IgG, EBNA IgG) in each CFS/ME subtype and the normal comparison group.

**Figure 2, panel E.** Distribution of categories of EBV serostatus (seronegative, primary / reactivation, late phase of infection) in the CFS/ME subtypes, A to H, in CFS/ME (all subtypes combined) and in Normal controls.

**Figure 2, panel F.** Log (base 2) of fold-difference values of 10 human genes known to be important in EBV infection, in 8 CFS subtypes (A – H).

**Table 1.** Patient information including age, sex, symptoms and questionnaire results summarising fatigue severity, pain, sleep, general function, and associated symptoms for CFS/ME patients and Normal blood donors enrolled in microarray and real-time PCR studies, respectively.

Clinical parameter	CFS/ME patients in previous study [7] (n=55)	CFS/ME patients, previously untested (n=53)	Q-CFS/ME patients* (n=6)	All CFS/ME patients (n=117)	Endogenous Depression patients (n=14)	Normal blood donors (n=29)
Gender (M:F)	19:36	10:46	6:0	35:82	4:10	14:15
Mean age (years)	41.6	40.25	41.5	41.3	41.36	44.6
Mean duration of disease (years:months)	3.17	2.9	5.7	3.4	0:6	N/A
<b>Symptoms / signs</b>						
Headache	26	30	1	57	5	1
Sore throat	27	29	0	56	1	1
Poor memory / concentration	30	46	4	80	11	3
Muscle pain	37	42	6	85	5	2
Muscle weakness	36	31	5	72	2	1
Joint pain	41	52	6	99	8	1
Post-exertional malaise	47	54	5	106	9	2
Sleep problem	44	24	0	68	4	3
Gastrointestinal problems	35	36	2	73	6	1
Fainting / dizziness	25	45	5	75	8	1
Numbness / tingling	24	25	2	51	1	0
Tender lymphadenopathy	27	22	2	51	0	0
<b>Mean scores</b>						
Physical fatigue (Chalder)	16.13	14.36	10.83	15.15	14.00	7.69
Mental fatigue (Chalder)	8.05	7.34	6.00	7.98	7.42	4.24
McGill Pain Questionnaire	15.28	18.57	18.80	17.58	9.67	2.48
Sphere Questionnaire	11.25	11.21	7.33	10.87	12.45	2.07
SF-36 Questionnaire	46.45	38.65	52.85	45.12	46.19	83.61
Pittsburgh Sleep Quality Index	10.22	10.00	8.17	10.01	12.25	4.28

N/A, not applicable

\*These 6 Q-CFS/ME patients were all part of the 1989 Birmingham Q-CFS/ME outbreak cohort.

**Table 2.** CFS/ME-associated genes and transcription factors in patients with CFS/ME, Q fever-associated CFS/ME and endogenous depression.

Gene symbol	GenBank Accession	Taqman assay ID***	CFS/ME (n=108)		Q-CFS/ME (n=6)		Endogenous depression (n=14)	
			Fold difference	P value	Fold difference	P value	Fold difference	P value
ABCD4*	NM_020323	Hs00245340_m1	2.21	0.01	3.01	0.031	1.42	0.26
ACTR3	NM_005721	Hs00828586_m1	13.53	0.0029	17.77	0.04	1.22	0.72
AKAP10	NM_007202	Hs00183673_m1	5.22	0.01	6.28	0.031	1.16	0.38
ANAPC11*	NM_016476	Hs00212858_m1	2.57	0.006	1.47	0.002	1.11	0.37
ANAPC5	NM_016237	Hs00212120_m1	2.04	0.002	1.07	0.045	1.32	0.392
APP	NM_201413	Hs00169098_m1	1.42	0.00003	0.23	0.001	1.59	0.021
ARL4C	NM_005737	Hs00255039_s1	7.15	0.00001	5.25	0.0023	1.18	0.76
ARPC5	NM_005717	Hs00271722_m1	3.71	0.000008	4.26	0.0047	1.46	0.49
ARSD	NM_001669	Hs00534692_m1	1.62	0.001	1.65	0.05	1.07	0.133
ATP6V1C1	NM_001695	Hs00184625_m1	2.66	0.0009	2.03	0.021	1.23	0.75
BCOR	NM_017745	Hs00372369_m1	1.90	0.0045	2.37	0.007	1.09	0.28
BMP2K	NM_198892	Hs00214079_m1	8.05	0.01	14.27	0.04	1.18	0.125
BRMS1*	NM_015399	Hs00363036_m1	3.08	0.0002	2.43	0.037	1.28	0.194
CD2BP2*	NM_006110	Hs00272036_m1	4.12	0.000084	5.15	0.001	1.44	0.334
CD47	NM_198793	Hs00179953_m1	3.38	0.0007	2.60	0.002	1.07	0.125
CEP350	NM_014810	Hs00402774_m1	3.85	0.001	6.49	0.01	1.36	0.803
CITED2	NM_006079	Hs00366696_m1	5.28	0.000031	6.21	0.049	1.33	0.172
CMTM6	NM_017801	Hs00215083_m1	3.61	0.014	6.31	0.046	1.21	0.405
CREBBP	NM_004380	Hs00231733_m1	7.02	0.02	9.82	0.025	1.61	0.021
CRK	NM_016823	Hs00180418_m1	1.98	0.000044	1.29	0.0003	1.40	0.683
CTBP1	NM_001328	Hs00179922_m1	5.13	0.071	4.16	0.02	1.45	0.134
CXCR4	NM_003467	Hs00607978_s1	13.46	0.00009	28.13	0.007	1.05	0.128
EBI2	NM_004951	Hs00270639_s1	5.99	0.002	26.16	0.011	0.88	0.687
EGR1	NM_001955	Hs00152928_m1	1.69	0.03	0.34	0.026	1.33	0.65
EGR3	NM_004421	Hs00231780_m1	2.11	0.017	X	X	X	X
EIF2B4*	NM_172195	Hs00248984_m1	2.87	0.0026	1.13	0.048	0.58	0.739
EIF3S10	NM_003750	Hs00186707_m1	2.10	0.0034	1.55	0.067	1.29	0.295
EIF4G1*	NM_198241	Hs00191933_m1	2.42	0.0007	0.34	0.035	1.16	0.165
EIF4G3	NM_003760	Hs00186804_m1	2.17	0.00012	3.22	0.0079	1.35	0.83
ETS1	NM_005238	Hs00901425_m1	30.82	0.0008	37.57	0.055	1.09	0.761
FAM126B	NM_173822	Hs00545158_m1	3.19	0.01	5.52	0.03	1.26	0.906
FNTA	NM_002027	Hs00357739_m1	3.86	0.0007	2.80	0.001	1.24	0.254
GABARAPL1*	NM_031412	Hs00744468_s1	5.27	0.00042	1.83	0.008	1.47	0.525
GABPA	NM_002031	Hs00745591_s1	15.40	0.0001	1.91	0.027	1.12	0.716
GCN1L1	NM_006836	Hs00412445_m1	1.18	0.00072	0.70	0.0015	1.07	0.443
GLTSCR2	NM_015710	Hs00414236_m1	5.49	0.0016	5.03	0.038	1.17	0.807
GNAS	NM_080425	Hs00255603_m1	2.37	0.000045	1.56	0.0021	1.56	0.004
GSN*	NM_198252	Hs00609276_m1	2.56	0.00037	2.40	0.01	1.11	0.312
GTF2A2	NM_004492	Hs00362112_m1	1.08	0.002	0.52	0.039	1.13	0.375
HIF1A	NM_001530	Hs00153153_m1	0.66	0.019	2.67	0.012	1.28	0.255
IFNAR1	NM_000629	Hs00265057_m1	3.30	0.00025	3.02	0.009	1.32	0.853
IL10RA*	NM_001558	Hs00387004_m1	1.34	9.87E-06	X	X	X	X
IL6R	NM_000565	Hs00794121_m1	2.49	0.06	X	X	X	X
IL6ST	NM_002184	Hs00174360_m1	3.34	0.0011	1.67	0.034	1.36	0.617

IL7R	NM_002185	Hs00233682_m1	0.52	0.032	X	X	X	X
JAK1	NM_002227	Hs00233820_m1	12.73	0.0000008	15.51	0.04	1.05	0.623
KHSRP*	NM_003685	Hs00269352_m1*	1.82	0.00026	0.35	0.0016	1.22	0.55
MAPK9	NM_139070	Hs00177102_m1	1.58	0.045	1.29	0.05	0.95	0.213
METTL3	NM_019852	Hs00219820_m1	1.30	0.0001	0.77	0.01	1.17	0.215
MRPL23*	NM_021134	Hs00221699_m1	2.62	0.001	0.80	0.029	1.36	0.79
MRPS6	NM_032476	Hs00606808_m1	2.75	0.025	1.87	0.014	1.34	0.451
MRRF	NM_138777	Hs00751845_s1	8.23	0.0004	2.84	0.03	1.22	0.25
MSN**	NM_002444	Hs00792607_mH	4.85	0.0016	7.49	0.002	1.35	0.962
MTMR6	NM_004685	Hs00395064_m1	6.60	0.0025	4.12	0.048	1.12	0.15
NFKB1	NM_003998	Hs00231653_m1	5.01	0.00027	5.01	0.001	1.28	0.41
NHLH1	NM_005589	Hs00271582_s1	58.31	7.00E-04	X	X	X	X
NR1D2	NM_005126	Hs00233309_m1	2.06	0.00016	1.56	0.0006	0.73	0.96
NTE*	NM_006702	Hs00198648_m1	2.92	0.001	7.34	0.02	1.49	0.579
NUFIP2	NM_020772	Hs00325168_m1	2.37	0.001	2.00	0.046	1.31	0.929
PAPOLA	NM_032632	Hs00413685_m1	0.62	0.00021	0.45	0.001	1.37	0.672
PDCD2*	NM_002598	Hs00751277_sH	5.38	0.008	X	X	0.62	0.029
PDCD6	NM_013232	Hs00737034_m1	2.54	0.0002	2.19	0.01	1.69	0.015
PEX16*	NM_004813	Hs00191337_m1	3.98	0.0061	3.32	0.028	0.68	0.776
PGM2	NM_018290	Hs00217619_m1	4.28	0.000001	3.50	0.0014	1.07	0.308
PIK3R1	NM_181523	Hs00236128_m1	4.04	0.005	2.60	0.01	1.14	0.208
PKN1*	NM_213560	Hs00177028_m1	4.58	0.0003	3.95	0.01	1.03	0.887
POLR2G*	NM_002696	Hs00275738_m1	2.71	0.001	1.00	0.039	0.77	0.916
PPP2R5C	NM_002719	Hs00604902_m1	4.65	0.013	8.21	0.045	1.30	0.906
PRKAA1	NM_006251	Hs01562315_m1	4.19	0.0002	2.18	0.001	1.29	0.56
PRKAR1A	NM_002734	Hs00267597_m1	3.55	0.0000004	2.31	0.0001	1.23	0.83
PUM2	NM_015317	Hs00209677_m1	2.73	0.00078	2.33	0.002	1.35	0.82
RAP2C	NM_021183	Hs00221801_m1	6.74	0.013	4.37	0.043	1.46	0.69
REPIN1	NM_013400	Hs00274221_s1	4.51	0.00001	2.13	0.01	1.26	0.41
RNF141	NM_16422	Hs00212656_m1	6.49	0.00000079	7.44	0.0003	1.19	0.411
SELENBP1	NM_003944	Hs00187625_m1	10.57	0.001	7.00	0.02	1.06	0.104
SFXN1	NM_022754	Hs00224259_m1	1.69	0.041	0.69	0.037	1.00	0.24
SHPRH	NM_173082	Hs00542737_m1	0.56	0.02	0.69	0.03	1.00	0.303
SNAP23	NM_003825	Hs00187075_m1	7.00	0.0006	3.17	0.01	1.10	0.132
SORL1	NM_003105	Hs00268342_m1	1.67	4.10E-08	X	X	X	X
SOS1	NM_005633	Hs00362308_m1	1.02	0.001	1.02	0.037	1.27	0.52
TAF11	NM_005643	Hs00194573_m1	1.17	0.001	0.00	0.02	1.40	0.57
TCF3	NM_003200	Hs00413032_m1	2.40	0.03	1.63	0.068	1.29	0.86
TDP1	NM_018319	Hs00217832_m1	3.12	0.001	3.16	0.01	1.12	0.83
TNFRSF1A	NM_001065	Hs00533560_m1	12.37	0.004	18.52	0.03	0.86	0.279
UBTF	NM_014233	Hs00610729_g1	6.38	0.002	2.40	0.011	1.09	0.297
USP38	NM_032557	Hs00261419_m1	3.35	0.01	4.98	0.078	1.43	0.367
WAPAL	NM_015045	Hs00386162_m1	3.94	0.003	3.69	0.026	1.17	0.44
WDR26	NM_025160	Hs00228535_m1	1.36	0.0008	0.71	0.01	1.48	0.95

\* genes found in pilot study [13]


\*\* genes found in study using differential display / PCR [7]

\*\*\*Taqman assays were those pre-designed by Applied Biosystems, Warrington, UK.

Table 3. Fold-difference values for 88 genes in each of 8 subtypes (A – H) in 114 CFS/ME patients. For each subtype, genes with fold-difference values of  $\geq 1.5$  up- or down-regulated, as compared with normals, are highlighted in grey. Genes without values for the subtypes are those for which there was missing data for one or more subtypes. Boxes with borders indicate genes targeted by existing drugs, and those CFS/ME subtypes in which there may be a rationale for a trial of a particular drug (see Results).


Gene symbol	Genbank Accession	CFS/ME subtype							
		A	B	C	D	E	F	G	H
ABCD4*	NM_020323	1.40	0.60	0.81	4.40	10.61	7.02	1.32	0.93
ACTR3	NM_005721	10.17	8.03	4.34	25.73	13.95	6.75	27.57	5.35
AKAP10	NM_007202	3.83	3.25	1.68	8.39	5.59	6.61	4.89	1.64
ANAPC11*	NM_016476	2.53	2.66	4.34	3.74	1.59	4.16	2.27	
ANAPC5	NM_016237	1.13	1.26	4.49	1.92	0.78	0.00	2.96	2.95
APP	NM_201413	0.63	1.73	1.42	0.56	4.64	0.84	0.84	2.58
ARL4C	NM_005737	6.62	7.40	2.72	5.85	7.82	8.76	6.68	2.81
ARPC5	NM_005717	2.55	0.81	1.53	5.65	4.87	3.41	4.92	3.01
ARSD	NM_001669	0.64	1.17	1.51	4.60	2.62	0.26	0.12	2.19
ATP6V1C1	NM_001695	1.99	3.80	3.38	2.43	2.06	0.72	3.63	4.55
BCOR	NM_017745	1.42	2.22	1.78	2.30	6.52	1.13	2.65	2.57
BMP2K	NM_198892	8.96	4.83	2.62	16.42	7.76	3.78	11.57	2.06
BRMS1*	NM_015399	1.31	4.38	2.44	1.53	4.62	7.06	2.57	3.83
CD2BP2*	NM_006110	3.89	1.37	2.21	6.77	4.52	1.33	5.99	3.55
CD47	NM_198793	2.60	6.90	3.37	3.66	4.06	0.95	4.13	2.75
CEP350	NM_014810	3.50	4.47	3.66	5.30	4.50	1.22	5.04	2.04
CITED2	NM_006079	6.43	6.84	1.97	4.95	6.02	4.40	5.50	3.42
CMTM6	NM_017801	3.10	3.70	0.69	10.04	7.81	4.77	1.71	0.73
CREBBP	NM_004380	7.11	1.62	1.09	13.34	5.46	2.61	8.99	3.62
CRK	NM_016823	1.83	5.57	1.26	2.82	4.89	1.03	2.25	2.02
CTBP1	NM_001328	4.95	4.98	1.05	8.62	15.44	3.43	2.42	2.73
CXCR4	NM_003467	13.47	2.18	2.03	28.10	17.57	1.48	10.29	3.57
EBI2	NM_004951	5.67	1.41	2.31	14.93	5.99	0.76	0.42	4.47
EGR1	NM_001955	0.49	2.85	2.42	0.30	0.27	1.00	1.98	2.96
EGR3	NM_004421	0.95	1.33	0.46		5.36		1.39	0.98
EIF2B4*	NM_172195	1.44	0.52	1.33	6.00	3.48	0.15	1.69	2.08
EIF3S10	NM_003750	1.43	4.42	2.10	1.72	1.48	1.25	2.83	6.16
EIF4G1*	NM_198241	1.13	3.47	3.52	0.99	1.39	2.30	4.53	14.27
EIF4G3	NM_003760	2.40	0.79	0.77	5.46	27.42	1.09	3.62	1.55
ETS1	NM_005238	35.12	4.63	4.16	52.65	30.36	17.54	24.17	6.91
FAM126B	NM_173822	2.04	0.63	0.91	10.18	5.51	2.59	1.31	0.71
FNTA	NM_002027	1.39	5.72	2.99	3.88	5.07	2.14	7.88	4.06
GABARAPL1*	NM_031412	6.08	6.42	3.37	2.93	8.49	2.58	6.23	5.74
GABPA	NM_002031	11.96	8.56	21.93	3.10	5.71	25.83	13.38	55.99
GCN1L1	NM_006836	0.80	1.40	1.91	0.44	5.85	1.13	1.59	2.38
GLTSCR2	NM_015710	3.68	2.46	0.53	4.94	6.98	4.07	10.28	0.80
GNAS	NM_080425	1.72	1.13	1.81	3.62	3.18	1.96	3.47	2.20
GSN*	NM_198252	1.73	1.27	1.69	3.82	2.36	1.64	3.51	5.81
GTF2A2	NM_004492	0.71	0.53	1.21	0.53	2.19	0.48	1.65	0.87


HIF1A	NM_001530	2.04	0.87	0.82	5.14	4.22	1.66	4.65	1.35
IFNAR1	NM_000629	1.86	0.17	0.79	3.55	5.53	1.41	7.17	0.91
IL10RA*	NM_001558	1.12	2.68	0.74			2.31	1.01	1.76
IL6R	NM_000565	2.19		2.47			2.78	2.67	
IL6ST	NM_002184	2.61	1.49	4.81	3.14	3.07	2.67	3.76	
IL7R	NM_002185	1.43	0.91	1.66			1.46	2.06	1.33
JAK1	NM_002227	9.72	7.84	3.29	28.88	9.80	11.17	18.75	6.19
KHSRP*	NM_003685	0.42	1.03	0.91	0.61	1.15	0.75	1.07	1.62
MAPK9	NM_139070	1.16		1.62	1.68	1.83	0.00	2.51	
METTL3	NM_019852	0.81	1.38	0.64	1.72	2.92	1.08	1.81	0.68
MRPL23*	NM_021134	2.34	0.97	1.23	4.15	4.20	1.56	2.56	2.06
MRPS6	NM_032476	2.03	0.92	2.93	3.05	7.75	1.77	1.95	2.00
MRRF	NM_138777	10.11	13.30	3.96	2.03	9.28	1.33	9.70	7.34
MSN**	NM_002444	3.20	1.66	1.81	9.47	7.86	3.13	8.58	2.12
MTMR6	NM_004685	3.71	11.73	2.61	7.73	7.33	2.67	14.97	2.58
NFKB1	NM_003998	3.74	0.91	0.65	8.83	6.51	4.10	7.30	1.55
NHLH1	NM_005589	26.32	37.92	49.09			66.39	51.25	126.29
NR1D2	NM_005126	1.40		2.31	4.57	3.69	1.27	2.50	2.29
NTE*	NM_006702	1.75	0.31	0.89	3.92	4.37	1.30	3.87	1.43
NUFIP2	NM_020772	1.55	1.90	1.81	2.83	2.10	1.84	3.50	2.31
PAPOLA	NM_032632	0.47	0.52	0.29	0.79	4.73	0.58	1.25	0.32
PDCD2*	NM_002598	3.83	3.44	2.94	5.00	5.74	5.88	5.36	7.37
PDCD6	NM_013232	1.96	2.72	2.53	2.16	4.79	2.69	2.85	2.16
PEX16*	NM_004813	2.10	16.10	2.04	8.88	5.92	0.00	2.90	2.80
PGM2	NM_018290	3.23	3.62	2.16	5.99	5.72	4.89	6.13	3.36
PIK3R1	NM_181523	2.06	4.55	0.58	7.17	7.31	0.95	5.48	0.82
PKN1*	NM_213560	2.25	3.76	1.27	6.67	6.09	2.39	8.14	2.84
POLR2G*	NM_002696	1.09	5.58	2.06	1.91	6.01	2.60	3.82	2.91
PPP2R5C	NM_002719	2.78	2.62	1.28	9.50	6.14	1.63	7.87	0.84
PRKAA1	NM_006251	2.14	4.10	3.42	3.53	4.17	6.87	7.13	3.11
PRKAR1A	NM_002734	2.05	1.85	2.56	4.14	3.66	2.41	6.35	5.41
PUM2	NM_015317	2.81	1.69	0.87	2.85	5.04	1.49	3.84	2.22
RAP2C	NM_021183	2.69		2.56	4.75	5.35	25.28	10.61	1.95
REPIN1	NM_013400	2.37	3.85	3.12	1.92	6.62	8.53	7.06	6.52
RNF141	NM_16422	3.64	0.64	2.10	9.85	11.45	6.08	10.83	2.09
SELENBP1	NM_003944	7.88	9.51	3.46	22.18	7.54	2.84	7.65	5.70
SFXN1	NM_022754	1.37	3.46	1.58	1.35	1.40	1.67	1.99	1.72
SHPRH	NM_173082	0.82		1.07	0.21	7.17	0.00	0.64	
SNAP23	NM_003825	3.46	0.45	1.89	12.62	13.33	4.15	10.19	1.43
SORL1	NM_003105	1.40	1.91	1.60			2.01	1.52	2.47
SOS1	NM_005633	0.70		0.81	1.69	1.09	0.29	1.61	0.90
TAF11	NM_005643	0.56		1.35	1.05	2.13	0.00	0.21	1.23
TCF3	NM_003200	2.00	0.94	1.08	2.83	3.96	3.54	2.52	2.65
TDP1	NM_018319	1.60	5.50	1.38	4.80	11.55	0.96	4.24	
TNFRSF1A	NM_001065	11.96	4.07	1.36	18.01	13.25	3.30	17.81	2.06
UBTF	NM_014233	2.88	3.59	1.82	6.03	6.46	4.81	10.91	6.44
USP38	NM_032557	2.66		0.71	7.40	4.27	7.18	2.94	1.02
WAPAL	NM_015045	2.97		5.13	3.63	2.78	1.24	6.04	2.97
WDR26	NM_025160	0.84	0.09	0.63	2.18	1.53	0.80	2.74	1.23





WDR26  
 SOS1  
 EIF2B4  
 PAPOLA  
 GTF2A2  
 TAF11  
 ARSD  
 KHSRP  
 SHPRH  
 GCN1L1  
 APP  
 PPP2R5C  
 PIK3R1  
 GLTSCR2  
 USP38  
 CMTM6  
 CTBP1  
 UBT1  
 PRKAR1A  
 NUFIP2  
 PDCCD2  
 REPIN1  
 PRKAA1  
 PDCCD6  
 SELENBP1  
 PKN1  
 MTMR6  
 TNFRSF1A  
 BMP2K  
 PGM2  
 JAK1  
 ACTR3  
 ETS1  
 AKAP10  
 CITED2  
 ARL4C  
 SFXN1  
 POLR2G  
 MAPK9  
 FNTA  
 MRRF  
 GABARAPL1  
 WAPAL  
 CEP350  
 CD47  
 MRPS6  
 IL7R  
 IL6ST  
 TCF3  
 SNAP23  
 RNF141  
 MSN  
 GNAS  
 ARPC5  
 NFKB1  
 HIF1A  
 PUM2  
 MRPL23  
 CREBBP  
 CXCR4  
 CD2BP2  
 PEX16  
 NR1D2  
 TDPI  
 CRK  
 BCOR  
 RAP2C  
 BRMS1  
 GSN  
 SORL1  
 NHLH1  
 IL6R  
 GABPA  
 ANAPC11  
 EIF4G1  
 EIF3S10  
 ATP6V1C1  
 NTFE  
 IFNAR1  
 METTL3  
 EGR3  
 EIF4G3  
 FAM126B  
 ABCD4  
 EBI2  
 ANAPC5  
 IL10RA  
 EGR1


A  
B  
C  
D  
E  
F  
G  
H











Log base 2  
fold-difference  
of RQ gene  
in CFS subtype  
versus Normals

